AnaptysBio, Inc. (ANAB) Guidance & Earnings Results
On 2026-05-12 AnaptysBio, Inc. reaffirmed guidance: "Expects >$390M annualized Jemperli royalties by 2029; anticipates paydown of ~$325M debt by Q2…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ANABAnaptysBio, Inc.Follow ANAB — free
—
Price chart with a free account
- Market cap
- 1.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 12 May 26 | Reaffirmed | Expects >$390M annualized Jemperli royalties by 2029; anticipates paydown of ~$325M debt by Q2 2027 · full year |
| 3 Mar 26 | Raised | Expects >$390M annualized Jemperli royalties by 2029 at GSK peak sales >$2.7B. · full year |
| 6 Aug 25 | Reaffirmed | Cash runway through year-end 2027 · full year |
AnaptysBio, Inc. — questions
- What guidance did AnaptysBio, Inc. give?
- On 2026-05-12: "Expects >$390M annualized Jemperli royalties by 2029; anticipates paydown of ~$325M debt by Q2 2027"
- When does AnaptysBio, Inc. report earnings?
- AnaptysBio, Inc.'s next earnings report is expected on 2026-11-10.
Every figure on this page comes from AnaptysBio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.